Importantly, anti-leukemia effects were abrogated in immunocompromised mice and the leukemia cells did not express MERTK themselves, indicating that the therapeutic activity was caused by immune-mediated effects and not direct leukemia cell killing [65,66]. The gene discussed is MERTK; the disease is leukemia.